PDSB - Latest News
PDS Biotechnology Corporation (PDSB), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $89.5M. Beta to the broader market is 1.45.
The article list below shows the most recent PDSB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PDSB Headlines
PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com - Oct 14, 2026
PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might d
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
globenewswire.com - Oct 6, 2026
PRINCETON, N. J.
PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Update
defenseworld.net - Sep 27, 2026
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of a significant increase in short interest in September. As of Septemb
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology
globenewswire.com - Sep 22, 2026
39. 3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in meta
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
globenewswire.com - Sep 14, 2026
Gross Proceeds of $11. 3 Million at Initial Closing Transaction Led by Dr.
How News Affects PDSB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PDSB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PDSB news questions
- What is the latest PDSB news headline?
- The most recent PDSB headline (Oct 14, 2026) is "PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PDSB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PDSB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PDSB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.